PolTREG has released long-term data from its Phase I and II trials of PTG-007.
PTG-007 is an autologous polyclonal T-regulatory cell therapy (Treg) that is currently being investigated in a range of autoimmune diseases, including type-1 diabetes and multiple sclerosis (MS).
The results show that the T-reg therapy can treat early onset type-1 diabetes (T1D), resulting in the clinical remission of patients for up to 12 years.
Notably, a subset of the patient population in the trials also remained insulin-independent for up to 24 months after treatment with PTG-007.
PolTREG found that the best results were observed in patients who were given Treg therapy in combination with standard anti-CD20 treatments such as rituximab.
There were no severe adverse events reported in patients who receievd PTG-007.
The company is currently looking to publish the findings in a peer-reviewed journal, while also seeking funding for the Phase II/III study of PTG-007 for the treatment of early-onset T1D.
PolTREG's CEO, Prof. Piotr Trzonkowski, commented: “People with type-1 diabetes understand the life-long commitment needed for their care. This is why the results of treating patients over such a long period with our cellular therapy PTG-007 is so important. Today’s results are extremely encouraging, and show that some patients remain in clinical remission for up to 12 years after initial treatment."
"This makes us very eager to launch a pivotal study of PTG-007 as soon as we find a suitable partner. We believe that PTG-007 has the potential to free many type-1 diabetics from the life-long burden of having to take frequent insulin injections, and the serious long-term complications of the disease,”
[Image credit: National Institute of Allergy and Infectious Diseases]